Sir Spheres UK information
SIR-Spheres Y90 resin microspheres - registered and available in UK and Europe for over 10 years. During this time Sirtex has worked in partnership with clinicians to develop an extensive clinical study programme including RCT’s. One of which, SIRFLOX - is about to report its findings and is the first RCT of its kind combining a medical device with chemotherapy in a first line treatment setting of inoperable liver metastases from colorectal cancer. See SIRFLOX PDF and FOXFIRE and FOXFIRE GLOBAL
By previous design, the data of FOXFIRE and FOXFIRE Global randomised controlled studies will be combined with the findings of 500-patient SIRFLOX study to form a database of more than 1,000 patients that has sufficient statistical power to evaluate whether first-line SIR-Spheres microspheres in combination with a standard-of-care chemotherapy versus chemotherapy alone can significantly increase the Overall Survival of patients with colorectal cancer liver metastases.
In the UK SIR-Spheres Y90 resin microspheres has a licence for the following indications: for the treatment of patients with advanced non-operable liver cancer.
The licence covers all primary liver cancers and all metastatic liver cancers.
Private or self-funding patients: could have any type of in-operable liver cancer treated.
Most private health insurance covers the whole procedure costs and covers the following inoperable liver tumours from: mCRC, HCC, intra-hepatic cholangio carcinoma, nMETS, metastatic breast cancer, ocular melanoma liver mets.
SIR-Spheres Y90 resin microspheres (SIRT – Selective Internal Radiation Therapy) has positive NICE IPG guidance in mCRC and HCC please see NICE pdf's below.
Selective internal radiation therapy for primary hepatocellular carcinoma
Selective internal radiation therapy for non-resectable colorectal metastases in the liver
NHS Patients: The newly formed NHS England provided funding for Selective Internal Radiation Therapy (SIRT) SIR-Spheres Y90 resin microspheres under a new initiative called “Commissioning through Evaluation” (CtE) in June 2013. NHS Scotland and NHS Wales have also adopted the same process.
This covers two groups of patients and in brief the criteria for these are:
Colorectal Liver Metastases
Inoperable liver predominant disease
Progressed following oxaliplatin & irinotecan chemotherapy or intolerant to chemotherapy
Performance status 0 or equal to 2
Must have greater than 3 months life expectancy
Intrahepatic Cholangiocarcinoma
Inoperable liver predominant disease
Progressed on Gemcitabine and Cisplatin or Intolerant to chemotherapy
Performance status 0 or equal to 2
Must have greater than 3 months life expectancy
England refer to 10 CTE SIRT commissioned centres:
- St James Hospital -Leeds Teaching Hospitals NHS Trust
- The Freeman Hospital - Newcastle upon Tyne Hospitals NHS Trust
- The Christie NHS Foundation Trust – Manchester
- City Hospital - Nottingham University Hospitals NHS Trust
- Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust
- (QE temporarily Refer to Nottingham or Oxford until further notice)
- Addenbrookes Hospital - Cambridge University Hospitals NHS Foundation Trust
- The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust
- The Royal Free London NHS Foundation Trust
- Kings College Hospital NHS Foundation Trust
- Southampton General Hospital - University Hospital Southampton NHS Foundation Trust
Scotland:
- Royal Infirmary of Edinburgh
Wales:
- Velindre Cancer Centre, Cardiff (South)
- The Christie NHS Foundation Trust - Manchester (North)
For more UK information or to discuss SirSpheres please contact Sandra Johnson Key Account Manager: sjohnson@sirtex-europe.com
Back to the SirSpheres page
